Stjernsward报告,目前,全世界共有癌症患者37×10~8万多人,而现有治疗手段仅能使1/3的病人治愈(发达国家)。不满意的疗效促使人们在寻求新的治疗途径。近百年来,人们已认识到光敏反应对生物体作用,但近十年才应用于人类癌瘤诊治。光敏反应包括三个基本因素:光敏剂,光和氧。60年代初,美国Lipson首先研制成功光敏剂一血卟啉衍生物(HPD);70年代初,早田义博等等用氪离子激光源,使光敏反应受到重视,促进了实验研究和临床应用的进展。至今全世界用此方法治疗癌瘤已超过两千人。现就光化学治疗(PCT)做一综述。实验研究 PCT基础研究工作是从体外培养肿瘤细胞,动 Stjernsward reported that at present, there are 37 million to 80,000 cancer patients worldwide, and the current treatment can only cure one third of the patients (developed countries). Unsatisfactory efficacy has prompted people to seek new treatments. In the past 100 years, people have recognized that photosensitivity reactions have effects on organisms, but it has been applied to the diagnosis and treatment of human cancers in the last decade. Photosensitive reactions include three basic factors: photosensitizers, light and oxygen. In the early 1960s, Lipson first developed a photosensitizer-hematoporphyrin derivative (HPD). In the early 1970s, Haeda Yoshihiro et al. used a cesium-ion laser to increase the sensitivity of photoreactions and promote experimental research and clinical application. progress. To date, more than 2,000 cancers have been treated with this method worldwide. A review of photochemical therapy (PCT) is now presented. Experimental research PCT basic research work is to cultivate tumor cells from